President's Award
Bristol-Myers Squibb Company
Presented to Chairman James M. Cornelius
The SECURE THE FUTURE® Technical Assistance Program (TAP) provides technical assistance, capacity-building tools and seed funding to extend community-based approaches for fighting HIV/AIDS to an increasing number of African countries and communities.
SECURE THE FUTURE® is Bristol-Myers Squibb’s pioneering $160 million initiative addressing HIV/AIDS in Africa. Since 1999, SECURE THE FUTURE® has engaged in more than 240 projects in more than 20 countries. Now in its third evolution, SECURE THE FUTURE® is leveraging its past investments by sharing its lessons across the continent.
 |
SECURE THE FUTURE®CECP presents the Pesident’s Award to Bristol-Myers Squibb Company for its SECURE THE FUTURE® Technical Assistance and Skills Transfer Program. |
TAP’s faculty of 50 experts from across Africa includes former grant recipients and partners who have excellent community engagement and program management skills. Uniquely, TAP represents a philanthropic program that has grown in impact, even with reduced financial support, by focusing on providing South-South (Africa to Africa) skills and knowledge transfer across Africa using human resources and community-based solutions.
A recent outcome evaluation by Accenture Development Program found that, “The South-South model executed by STF TAP is unique in its approach, having dramatic outcomes and doing so in a cost effective manner. It has proven to be an effective way to mobilize communities in the fight against HIV/AIDS, resulting in the training of more than 2,200 local resources and the support of over 1 million individuals affected by HIV/AIDS in hard-to-reach areas in just the 16 sites that we evaluated.”
The program is scalable for local needs and replicable precisely because of its local structure and objectives. Many community-based approaches applied to HIV/AIDS are being transferred to strengthen other Foundation programs around the globe. Additionally, the lessons learned around HIV in Africa are being applied to a new $100 million Foundation initiative addressing another difficult disease and population group, adult type 2 diabetes in the U.S., and especially among affected minority populations.
